Don’t miss our upcoming webinars. Subscribe today!
About this webinar:
In this webinar, presented by Marjut Huotari, Vice President of Healthcare Insights at Leger, you will learn about cancer patient and caregiver concerns as society opens. How do cancer patients feel? What risks are they willing to take?
About the presenter:
Marjut Huotari has a Bachelor and a Master of Business Administration from the Schulich School of Business, York University. She is a marketing professional with over 20 years of experience working with the pharmaceutical industry, including 14 years working in the pharmaceutical industry on the client side. With Leger, Marjut manages both qualitative and quantitative market research, conducting research with a variety of healthcare practitioners and patients. With her team, she aims to help her clients to understand the issues and help develop solutions.
View the Video: https://bit.ly/youtubeCancerCantWaitCCSNFourthLegersurveyonCOVID19andcancercare
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don't miss our upcoming webinars. Subscribe today!
Presented by: Marjut Huotari - Vice President, Healthcare Insights at Leger
In this webinar:
The Canadian Cancer Survivor Network commissioned Leger, a Canadian-owned polling and market research firm, to discover how the disruption of cancer care has affected Canadian cancer patients, survivors, and caregivers. This third survey Leger conducted for CCSN took place from June 10 to July 4, 2021.
Join CCSN and Leger as we present the results of the survey on COVID-19 and Cancer Care Disruption in Canada - Wave 3, and hear from members of the cancer community about how the pandemic has directly impacted them.
Watch the YouTube video: https://www.youtube.com/watch?v=CTomgU3AUSQ
To learn more about CCSN, visit us at survivornet.ca
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don't miss our upcoming webinars. Subscribe today!
Presented by: Marjut Huotari - Vice President, Healthcare Insights at Leger
In this webinar:
The Canadian Cancer Survivor Network commissioned Leger, a Canadian-owned polling and market research firm, to discover how the disruption of cancer care has affected Canadian cancer patients, survivors, and caregivers. This third survey Leger conducted for CCSN took place from June 10 to July 4, 2021.
Join CCSN and Leger as we present the results of the survey on COVID-19 and Cancer Care Disruption in Canada - Wave 3, and hear from members of the cancer community about how the pandemic has directly impacted them.
Watch the YouTube video: https://www.youtube.com/watch?v=CTomgU3AUSQ
To learn more about CCSN, visit us at survivornet.ca
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don’t miss our upcoming webinars: Subscribe today!
In this webinar:
Join CCSN and Marjut Huotari, VP-Healthcare Insights at Leger, as we present the results of the COVID-19 and Cancer Care Disruption in Canada Survey and hear from members of the cancer community about how the pandemic has directly impacted them.
View the video:
https://youtu.be/6ub1ot806-A
To learn more about CCSN, visit us at survivornet.ca
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don't miss our upcoming webinars! Subscribe today!
In this webinar:
In May-June, 2020, the Canadian Cancer Survivor Network (CCSN) commissioned Leger to conduct a national survey to evaluate the impact that COVID-19 has had on cancer patients, survivors, pre-diagnosis patients, and caregivers. The results of our first survey revealed that the pandemic response has triggered another public health crisis - the postponement and cancellation of essential cancer tests, procedures, and treatments.
CCSN commissioned Leger for a second survey in December, 2020 to evaluate the impact that the suspension of cancer services during the first wave is currently having on those who have been affected by cancer.
Join CCSN and Leger as we present the results of the COVID-19 and Cancer Care Disruption in Canada Survey - Wave 2 and hear from members of the cancer community about how the pandemic has directly impacted them.
View the YouTube video: https://youtu.be/qN4Hq7OtBys
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
About this Webinar: we’ll summarize the findings of a 10-minute online study conducted by Leger among cancer patients who experienced Long-COVID. We identified 119 cancer patients, diagnosed within the past 10 years, who developed symptoms or were diagnosed with Long-COVID. We primarily wanted to understand how Long-COVID impacted cancer patients and their ability to receive treatment. We also asked about the effect on their overall wellbeing, their ability to access Long-COVID treatments and assistance, and the ongoing impact to this day.
About this Presenter: Colette Faust is a Research Director at Leger (largest Canadian-owned market research company) and has 10 years of market research experience, spending the last 3 years in the healthcare industry. As a member of Leger’s North American Healthcare team, Colette has worked on both quantitative and qualitative healthcare research among healthcare professionals, patients, and the general population across a variety of topics including oncology. Colette received her B.A. in Psychology and Media & Communications from Muhlenberg College in Allentown, PA.
Don't miss our upcoming webinars! Subscribe today!
In April, CCSN virtually met with MPPs throughout Ontario to discuss our COVID-19 and Cancer Care - Wave 2 Survey. During these meetings, we discussed the difficulty cancer patients and pre-diagnosis patients have had with accessing cancer services during the pandemic and the importance of ensuring the cancer patients receive their 1st and 2nd vaccine doses in a timely manner.
In this webinar, CCSN's Public Policy Analyst Conrad will begin by sharing some of the highlights from our meetings with Ontario MPPs. He will then turn things over to our patient advocates and they will share some of their reflections from our meetings as well as their own experiences with accessing cancer care during the pandemic. Lastly, Conrad will take a closer look at the Ontario data from our survey.
View the YouTube video: https://youtu.be/05u4i89WFfQ
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
In this global pandemic, IBD patients and their healthcare providers from around the world share similar fears and concerns. SECURE-IBD is an international database to monitor and report on COVID-19 in IBD patients. By working across borders, we are learning how factors like age, other conditions, and IBD treatments impact COVID-19 outcomes. This slide deck also shares information about other research efforts that are ongoing to better understand the impact of COVID-19 on IBD patients.
The Foundation would like to thank AbbVie Inc., Genentech, Inc., Gilead Sciences, Inc., Janssen Biotech, Inc., Shire, and Takeda Pharmaceuticals U.S.A., Inc., sponsors of our COVID-19 materials. Additional support is provided through the Foundation’s annual giving program and individual donors.
This presentation summarizes the results of a June 2021 survey of veterinary professionals on the effects of the COVID-19 pandemic on veterinary practices and heartworm management
Primary medical care settings are ideal for treating chronic illnesses but are underutilized venues for addressing this particular chronic disease. Addiction treatment specialists are too few and many patients find this path to be unacceptable. The question becomes: how to get primary care medical providers to integrate the treatment of patients with opioid use disorders into their practices?
Different ways to accomplish this were the topic of the Louis Kolodner Memorial Lecture at MedChi for the second year in a row. Last year, Dr. Michael Fingerhood described the model that he has developed at Johns Hopkins Medicine. This year, Dr. Richard Schottenfeld, now the Chief of Psychiatry at Howard University, presented research studies done by Yale University and other centers. These studies demonstrated four successful interventions:
Methadone given to already stabilized opioid addiction patients in a primary care setting instead of a specialized opioid treatment program (OTP)
Buprenorphine along with medical counseling given in a primary care setting
An initial dose of buprenorphine given in a hospital emergency department along with a next-day follow up appointment for ongoing treatment
Injectable naltrexone, although more difficult to initiate for patients than was buprenorphine, was effective for those patients who were able to start it
Two barriers that needed to be reduced to achieve these successes were the disinclination of providers to use these medications and general pessimism about the prognosis of opioid use disorders. My hope is that as more successes are demonstrated, these barriers will slowly be lowered. For those interested in more details about these studies, I invite you to access the lecture slides, available here.
For more information contact: Slideshare@marcusevans.com
Presentation delivered by Donna Medina, Regional Director,OSF Hospice and Homecare Foundation at the marcus evans Home Care Leadership Summit held on July 13 & 14 2015 in Palm Beach FL.
Why screeing cancer patients for distress will increase disparities in psycho...James Coyne
Keynote address
Implementing screening of cancer patients for distress will not improve patient outcomes and may aggravate existing biases in who get psychosocial services.
Determining Prognosis in Cancer and Non-Cancer DiagnosisVITAS Healthcare
The goal of this webinar is to help healthcare professionals identify patients who have advanced illness and are no longer responding to curative care.
How is the Coronavirus Impacting Healthcare Perceptions and Behaviors? (Wave ...Ed Bennett
Research from Klein & Partners and The DRG
This year’s Omnibus is a bit different from past years. We focus the entire survey on consumer reactions to the Coronavirus and we will conduct three waves of this survey to track how these reactions change as we get past the ‘peak’ and move into our ‘new’ normal.
This presentation summarizes findings from the first wave conducted in early April. Wave II will field in late April/early May after the peak and the third wave will field sometime in late May/early June as we emerge in our new normal. Field times are fluid as we monitor the progress of this pandemic.
Also, this year, we are pleased that our long-time research partner and friends – The DRG – have partnered on this research with us.
Klein & Partners and The DRG would like to thank you for your extraordinary efforts during these unprecedented times in recent history to help our local communities keep safe and informed about the latest developments and the support available on the Coronavirus.
--Rob Klein, Founder & CEO, Klein & Partners
How general internists can participate in the continuum of care for patients with cancer. (Talk given at Internal Medicine Grand Rounds, St. Elizabeth Hospital, General Santos City, 10 Feb 2021.)
From surviving to thriving: cancer’s next challengePwC Russia
Рак-диагноз, который никто не хочет услышать. Приуроченный к Всемирному дню борьбы с раком отчет PwC рассказывает об историях тех, кто пережил этот страшный период жизни и не сдался.
Living with Advanced Breast Cancer: Challenges and Opportunitiesbkling
Musa Mayer -- breast cancer survivor, advocate, and author -- presents at SHARE in November 2011. To view a video about the First International Consensus on Metastatic Breast Cancer, visit www.sharecancersupport.org/mayer.
Study measures usage and sentiments toward telehealth. The results are weighted to be representative of the American adult population across standard demographics.
About the Webinar: Michelle Colero, Executive Director of Bladder Cancer Canada, will cover the essentials of bladder cancer facts and symptoms while also outlining the support and educational resources provided by Bladder Cancer Canada for those dealing with a diagnosis. Additionally, she’ll share ways individuals can contribute to raising awareness and supporting our community.
About the Webinar: Alcohol is classified as a Group one carcinogen and is estimated to be one of the top three causes of cancer deaths worldwide. Yet, over 40 per cent of people in Canada remain unaware that alcohol consumption increases the risk of developing at least nine cancers. In this presentation, we’ll look at what is and isn’t known about the relationship between alcohol and cancer. We’ll explore what the Canadian Cancer Society is doing to raise awareness of alcohol as a modifiable cancer risk factor, its commitment to funding world-leading research on this subject, and its advocacy for stronger policies that reduce, and increase awareness about the risk of cancer related to, alcohol consumption. Attendees will be invited to seek more information and/or take action on this important topic. We hope you’ll join us in learning more about cancer risk and alcohol — the most commonly used psychoactive substance in Canada.
More Related Content
Similar to CCSN Impact on Cancer Patients W4 Webinar June 23 2022.
Don’t miss our upcoming webinars: Subscribe today!
In this webinar:
Join CCSN and Marjut Huotari, VP-Healthcare Insights at Leger, as we present the results of the COVID-19 and Cancer Care Disruption in Canada Survey and hear from members of the cancer community about how the pandemic has directly impacted them.
View the video:
https://youtu.be/6ub1ot806-A
To learn more about CCSN, visit us at survivornet.ca
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don't miss our upcoming webinars! Subscribe today!
In this webinar:
In May-June, 2020, the Canadian Cancer Survivor Network (CCSN) commissioned Leger to conduct a national survey to evaluate the impact that COVID-19 has had on cancer patients, survivors, pre-diagnosis patients, and caregivers. The results of our first survey revealed that the pandemic response has triggered another public health crisis - the postponement and cancellation of essential cancer tests, procedures, and treatments.
CCSN commissioned Leger for a second survey in December, 2020 to evaluate the impact that the suspension of cancer services during the first wave is currently having on those who have been affected by cancer.
Join CCSN and Leger as we present the results of the COVID-19 and Cancer Care Disruption in Canada Survey - Wave 2 and hear from members of the cancer community about how the pandemic has directly impacted them.
View the YouTube video: https://youtu.be/qN4Hq7OtBys
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
About this Webinar: we’ll summarize the findings of a 10-minute online study conducted by Leger among cancer patients who experienced Long-COVID. We identified 119 cancer patients, diagnosed within the past 10 years, who developed symptoms or were diagnosed with Long-COVID. We primarily wanted to understand how Long-COVID impacted cancer patients and their ability to receive treatment. We also asked about the effect on their overall wellbeing, their ability to access Long-COVID treatments and assistance, and the ongoing impact to this day.
About this Presenter: Colette Faust is a Research Director at Leger (largest Canadian-owned market research company) and has 10 years of market research experience, spending the last 3 years in the healthcare industry. As a member of Leger’s North American Healthcare team, Colette has worked on both quantitative and qualitative healthcare research among healthcare professionals, patients, and the general population across a variety of topics including oncology. Colette received her B.A. in Psychology and Media & Communications from Muhlenberg College in Allentown, PA.
Don't miss our upcoming webinars! Subscribe today!
In April, CCSN virtually met with MPPs throughout Ontario to discuss our COVID-19 and Cancer Care - Wave 2 Survey. During these meetings, we discussed the difficulty cancer patients and pre-diagnosis patients have had with accessing cancer services during the pandemic and the importance of ensuring the cancer patients receive their 1st and 2nd vaccine doses in a timely manner.
In this webinar, CCSN's Public Policy Analyst Conrad will begin by sharing some of the highlights from our meetings with Ontario MPPs. He will then turn things over to our patient advocates and they will share some of their reflections from our meetings as well as their own experiences with accessing cancer care during the pandemic. Lastly, Conrad will take a closer look at the Ontario data from our survey.
View the YouTube video: https://youtu.be/05u4i89WFfQ
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
In this global pandemic, IBD patients and their healthcare providers from around the world share similar fears and concerns. SECURE-IBD is an international database to monitor and report on COVID-19 in IBD patients. By working across borders, we are learning how factors like age, other conditions, and IBD treatments impact COVID-19 outcomes. This slide deck also shares information about other research efforts that are ongoing to better understand the impact of COVID-19 on IBD patients.
The Foundation would like to thank AbbVie Inc., Genentech, Inc., Gilead Sciences, Inc., Janssen Biotech, Inc., Shire, and Takeda Pharmaceuticals U.S.A., Inc., sponsors of our COVID-19 materials. Additional support is provided through the Foundation’s annual giving program and individual donors.
This presentation summarizes the results of a June 2021 survey of veterinary professionals on the effects of the COVID-19 pandemic on veterinary practices and heartworm management
Primary medical care settings are ideal for treating chronic illnesses but are underutilized venues for addressing this particular chronic disease. Addiction treatment specialists are too few and many patients find this path to be unacceptable. The question becomes: how to get primary care medical providers to integrate the treatment of patients with opioid use disorders into their practices?
Different ways to accomplish this were the topic of the Louis Kolodner Memorial Lecture at MedChi for the second year in a row. Last year, Dr. Michael Fingerhood described the model that he has developed at Johns Hopkins Medicine. This year, Dr. Richard Schottenfeld, now the Chief of Psychiatry at Howard University, presented research studies done by Yale University and other centers. These studies demonstrated four successful interventions:
Methadone given to already stabilized opioid addiction patients in a primary care setting instead of a specialized opioid treatment program (OTP)
Buprenorphine along with medical counseling given in a primary care setting
An initial dose of buprenorphine given in a hospital emergency department along with a next-day follow up appointment for ongoing treatment
Injectable naltrexone, although more difficult to initiate for patients than was buprenorphine, was effective for those patients who were able to start it
Two barriers that needed to be reduced to achieve these successes were the disinclination of providers to use these medications and general pessimism about the prognosis of opioid use disorders. My hope is that as more successes are demonstrated, these barriers will slowly be lowered. For those interested in more details about these studies, I invite you to access the lecture slides, available here.
For more information contact: Slideshare@marcusevans.com
Presentation delivered by Donna Medina, Regional Director,OSF Hospice and Homecare Foundation at the marcus evans Home Care Leadership Summit held on July 13 & 14 2015 in Palm Beach FL.
Why screeing cancer patients for distress will increase disparities in psycho...James Coyne
Keynote address
Implementing screening of cancer patients for distress will not improve patient outcomes and may aggravate existing biases in who get psychosocial services.
Determining Prognosis in Cancer and Non-Cancer DiagnosisVITAS Healthcare
The goal of this webinar is to help healthcare professionals identify patients who have advanced illness and are no longer responding to curative care.
How is the Coronavirus Impacting Healthcare Perceptions and Behaviors? (Wave ...Ed Bennett
Research from Klein & Partners and The DRG
This year’s Omnibus is a bit different from past years. We focus the entire survey on consumer reactions to the Coronavirus and we will conduct three waves of this survey to track how these reactions change as we get past the ‘peak’ and move into our ‘new’ normal.
This presentation summarizes findings from the first wave conducted in early April. Wave II will field in late April/early May after the peak and the third wave will field sometime in late May/early June as we emerge in our new normal. Field times are fluid as we monitor the progress of this pandemic.
Also, this year, we are pleased that our long-time research partner and friends – The DRG – have partnered on this research with us.
Klein & Partners and The DRG would like to thank you for your extraordinary efforts during these unprecedented times in recent history to help our local communities keep safe and informed about the latest developments and the support available on the Coronavirus.
--Rob Klein, Founder & CEO, Klein & Partners
How general internists can participate in the continuum of care for patients with cancer. (Talk given at Internal Medicine Grand Rounds, St. Elizabeth Hospital, General Santos City, 10 Feb 2021.)
From surviving to thriving: cancer’s next challengePwC Russia
Рак-диагноз, который никто не хочет услышать. Приуроченный к Всемирному дню борьбы с раком отчет PwC рассказывает об историях тех, кто пережил этот страшный период жизни и не сдался.
Living with Advanced Breast Cancer: Challenges and Opportunitiesbkling
Musa Mayer -- breast cancer survivor, advocate, and author -- presents at SHARE in November 2011. To view a video about the First International Consensus on Metastatic Breast Cancer, visit www.sharecancersupport.org/mayer.
Study measures usage and sentiments toward telehealth. The results are weighted to be representative of the American adult population across standard demographics.
About the Webinar: Michelle Colero, Executive Director of Bladder Cancer Canada, will cover the essentials of bladder cancer facts and symptoms while also outlining the support and educational resources provided by Bladder Cancer Canada for those dealing with a diagnosis. Additionally, she’ll share ways individuals can contribute to raising awareness and supporting our community.
About the Webinar: Alcohol is classified as a Group one carcinogen and is estimated to be one of the top three causes of cancer deaths worldwide. Yet, over 40 per cent of people in Canada remain unaware that alcohol consumption increases the risk of developing at least nine cancers. In this presentation, we’ll look at what is and isn’t known about the relationship between alcohol and cancer. We’ll explore what the Canadian Cancer Society is doing to raise awareness of alcohol as a modifiable cancer risk factor, its commitment to funding world-leading research on this subject, and its advocacy for stronger policies that reduce, and increase awareness about the risk of cancer related to, alcohol consumption. Attendees will be invited to seek more information and/or take action on this important topic. We hope you’ll join us in learning more about cancer risk and alcohol — the most commonly used psychoactive substance in Canada.
Dr. Rob Rutledge returns for his first webinar of 2024 to discuss the basics behind emotional intelligence. Learn how to develop greater emotional awareness, and learn how to settle fear and frustration. Dr. Rutledge will also share tips on how to live in a more peaceful and connected way as you navigate through your cancer journey.
About the Webinar: Health technology assessment (HTA), the approval process for drugs and healthcare technology, the processes and organizations that support them, such as Canadian Agency for Drugs and Technologies in Health (CADTH), have evolved over the years in response to changing healthcare system priorities and the need to establish their legitimacy. Don Husereau will provide an overview of current processes in Canada, and highlight their perceived (and real) shortcomings and what can be done to overcome these. He will highlight that some perceived weaknesses (such as review times) are not as bad as they appear while perceived strengths (such as stakeholder involvement) need considerable improvement. He will also discuss other opportunities for HTA to innovate and whether there are current plans to address these.
About this Webinar: The time between regulatory approval for new drugs and when drugs became publicly available to patients averaged 736 days (25 months) in 2022. This is double the average time reported in comparable Organisation for Economic Development (OECD) countries. This webinar will highlight variations in drug listing time for new drugs across time, provinces, and type of drugs (oncology vs. non-oncology). It will also present the specific phases involved in moving a drug from approval stage to listing, and the time spent in each. This Conference Board of Canada analysis uses IQVIA’s Market Access Metrics Database (2012 to 2023), which tracks all new products and their indications through the Canadian access journey.
About the Webinar: Learn about pancreatic cancer symptoms, diagnosis, treatment options, statistics, supports and barriers. The presentation will also include some helpful tools that can improve quality of life for those with pancreatic cancer, including the Craig's Cause's PERT (Pancreatic Enzyme Replacement Therapy) calculator and available patient support programs.
As referenced by John Adams in his 2024 CCSN Webinar on the US importing drugs from Canada, this is a slide deck from Health Canada which outlines the timetable and actions taken by the government on this particular issue.
About this Webinar: John Adams takes a dive behind the headlines, news stories and media releases to better understand any real threats to Canadian patients getting the prescription drugs they need.
About this Webinar: We know that methods of eating and diet are a large part of cancer care, but how can you make your diet work for you in your cancer journey? Dr. Rob Rutelege is back to present the latest science around healthy eating and cancer care. In addition, Dr. Rutledge will share the benefits of time-restricted eating, and how you can incorporate it into your daily routine.
Colorectal cancer is the second leading cause of cancer death in Canada, with approximately 24,100 Canadians diagnosed with the disease in 2023. The incidence of colorectal cancer has been declining in Canadians over 50 years of age, largely due to population-based screening programs. Recent evidence has shown, however, that rates have been increasing in adults younger than 50 years. Given that younger adults are typically classified as at low risk for colorectal cancer, this epidemiologic shift is cause for concern.
Individuals under the age of 50 now represent a significant number of colorectal cancer cases. The disease is often being diagnosed at a later stage, and tumour characteristics tend to be more lethal. As for what is accounting for the increasing trend, ongoing research efforts focus on environmental toxicities, lifestyle patterns, and the gut microbiome.
In this webinar, we will present an overview of the current evidence surrounding the rising rates of colorectal cancer in young adults and discuss the unique needs of this patient population, through screening, diagnosis, treatment, and survivorship. A young colorectal cancer patient will share his lived experience in managing this disease and the impact that cancer has had on himself and his family.
About this Talk: This talk will provide a nutritional perspective on the role of diet in cancer focusing on healthy fats known as omega-3 fatty acids. Sources, amounts and types of omega-3 fatty acids will be highlighted. Clinical and experimental evidence in support of a role for omega-3 fatty acids in the prevention and treatment of breast cancer will be presented. Lastly, some practical strategies to support a healthy diet will be shared.
About the Webinar: Genomic testing has already become commonplace in oncology, but exponential growth in more comprehensive genomic tests, other innovative tests and testing approaches in oncology, as well as a number of other therapeutic areas is expected in the coming years. With the emergence of more complex, more expensive, and more promising tests, policymakers and healthcare providers may be challenged to provide these to patients at the pace of innovation. Don Husereau will describe what conditions are necessary for equitable access to advanced innovative testing, how major Canadian provinces are doing, and what more needs to be done in the coming years to benefit all patients.
About this Webinar: This talk will explore breast screening for women 40-49. The benefits and harms for screening will be discussed, as well as what is unique about breast cancer in women in their 40s. In order to understand the controversy around current guidelines recommending against screening women 40-49, we will review the evidence upon which these guidelines are based, and their impact on breast cancer outcomes for these women.
About this Webinar: This presentation will discuss the pathway to pharmaceutical treatments in Canada that involve health technology assessment reviews and decision making. Observations on the current challenges and the importance of patient input to inform decision making will also be discussed. Finally, the key elements that can be critical to successful outcomes will be presented.
About this Webinar: When Canadians turn on the tap for a drink of water or a shower, we take for granted that the water is safe. Few are aware that old asbestos cement water pipes still deliver water to millions of people. As these pipes age and deteriorate, asbestos erodes into the water and poses health concerns, including cancer.
Dr. Meg Sears, Chair of the Board of Prevent Cancer Now, and board member Julian Branch will talk about the history of asbestos in water, the science behind ingested asbestos, and recent developments.
André Deschamps will show the results of the Europa UOMO Euproms studies. These are the first studies ever from patients for patients, measuring the burden of treatment. More than 5000 patients have shared with us their experiences after treatment. The data has been analyzed by the university of Rotterdam in the Netherlands and has been published in peer reviewed scientific papers.
This webinar will serve as an introduction to Cancer and Work, a website that “was designed to address the unique needs of cancer survivors with returning, remaining, changing work or looking for work after a diagnosis of cancer. The website provides newly created information, resources, and interactive tools for cancer survivors, healthcare providers, employers, and highlights helpful information from across the globe.” The talk will include 10 steps to return to work, and job search ideas for cancer survivors
This webinar will have two perspectives.
Jasveen will be presenting about the impact of cancer and treatment on a person’s physical, cognitive & mental health and how an Occupational therapist can work with the person to gradually overcome these challenges to return to work with or without modifications. The presentation will cover some case studies of past success with the opportunity to answer questions at the end.
Then we will hear from Jen who has experienced her own journey with breast cancer and how she advocated for herself and occupational therapy to help her return to full time employment.
Various cancer treatments can impact one’s gut health and digestive system. This presentation will discuss why a healthy gut is important to overall health. We will talk about the roles the gut is involved in beyond just digestion. We will also discuss nutrition strategies that will support our gut health and promote a healthy microbiome.
In this Webinar, participants will learn about:
– Balancing rising costs and a limited budget
– Eating healthily, food banks, other resources in your community
– Budget formats that work for cancer patients
– Money management
– Debit and credit management
– Credit counselling
– Consumer protection
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
CCSN Impact on Cancer Patients W4 Webinar June 23 2022.
1. Cancer Can’t Wait!
Fourth survey on COVID-19 and
Cancer Care reveals cancer patient &
caregiver concerns as society opens
Thursday June 23rd, 2022
1:00 pm
Presented by Marjut Huotari,
VP – Healthcare Insights, Leger
416-262-4200
1
2. Research context and objectives
Research methodology
• Recruitment
• Research methodology
Key findings
Conclusion
Q&A
1
2
3
4
5
OVERVIEW
2
3. RESEARCH CONTEXT AND OBJECTIVES
Leger, on behalf of the Canadian Cancer Survivor Network (CCSN), conducted a fourth wave of the study to assess
the extent to which the disruption of cancer care caused by COVID-19 impacts cancer patients and caregivers, from
an emotional and physical wellness perspective.
• Level of anxiety and concerns about receiving adequate cancer care now that COVID-19
restrictions are being lifted
• How are patients and caregivers interacting with the doctor managing their cancer
• virtual consults, in person visits, etc.
• How do they rate the quality of care in the past 6 months?
• COVID-19 vaccination among patients and caregivers
• Impact of COVID-19 restrictions being lifted
• Impact of relaxation of restrictions on daily life
• Perceptions about provincial government lifting restrictions
• Likelihood to continue to follow COVID-19 related precautions
• What could the government do to make patients and caregivers feel more comfortable
• % of cancer patients tested positive for COVID-19 and their COVID-19 journey
Key topics addressed
in the survey
3
4. RESEARCH METHODOLOGY – SAMPLE SIZE
This wave, data collection took place from April
13th to May 12th, 2022.
Previous wave, Total sample of 1,502 - data
collection took place from June 10th to July 4th,
2021.
Web survey of 1,353 Canadians, including
1,100 Canadians diagnosed with cancer,
and 253 Caregivers.
The survey was made available in both
English and French.
REGIONAL ACHIEVEMENTS
QUE 30%
ON 31%
AB 10%
BC 14% SK 3%
ATL 6%
MB 5%
4
5. RESEARCH METHODOLOGY – RECRUITMENT
SCREENING CRITERIA:
• 18 years or older and currently living in Canada
• Respondents qualified as:
A patient, if they were diagnosed with cancer
A caregiver, if a currently living family member / someone they
care for was diagnosed with cancer. A caregiver should be
supporting patients in either of the following ways:
• Provide emotional support
• Attend doctor’s appointments where their cancer may be discussed
• Look for information on treatment options, for example, on the Internet, or in books
• Support the person in other ways, e.g. by driving to and from doctor’s appointments
RECRUITMENT:
• All respondents were recruited via our LEO PANEL – Leger’s proprietary consumer panel
with nearly 500,000 members (largest in Canada)
5
7. KEY STUDY FINDINGS
Overall, cancer patients are significantly more likely to have CONSULTED an HCP in the past 6 months vs. during the
pandemic, more so in-person, and majority say they were HIGHLY SATISFIED WITH THE QUALITY OF CANCER CARE
received in the past 6 months.
LEVEL OF ANXIETY ABOUT RECEIVING ADEQUATE CANCER CARE DROPPED THROUGHOUT THE PANDEMIC from its
highest levels when COVID-19 was declared a pandemic; however, now as restrictions are being lifted, anxiety levels
are likely to rise again.
When prompted, respondents report being QUITE CONCERNED about their ability to be CARED FOR IN AN ER or a
HOSPITAL, SEE A DOCTOR IN-PERSON and being able to GET TESTS AND TREATMENT IN A TIMELY MANNER as
restrictions begin to be lifted.
Many respondents mention that they are NOT COMFORTABLE with their PROVINCIAL GOVERNMENT LIFTING
RESTRICTIONS, mainly because they believe that IT IS TOO SOON and COVID CONTINUES TO BE A THREAT.
Patients as well as caregivers indicate HIGH LIKELIHOOD to CONTINUE FOLLOWING COVID-19 SAFETY MEASURES,
including WEARING A MASK FOR THE FORESEEABLE FUTURE.
1
2
4
5
3
8
8. RESPONDENT PROFILE – PATIENTS
Even split by gender Tend to skew older: 64 YEARS (64) on average
Fairly regionally representative
across Canada
QUE 32%
ON 32%
AB 10%
BC 14%
SK 3% ATL 5%
MB 4%
BREAST (25%) and PROSTATE (19%) cancer
account for about 2 in 5 cases.
Other cancers among ~1 in 10 patients include
colon / rectal and melanoma.
25% 19%
Stage 1
27%
Stage 2
11%
Stage 3
10%
Stage 4 /
Metastatic
9%
Remission
31%
1 in 9 (13%) say they are unsure of their stage of cancer.
<2 YEARS
25%
2-5 YEARS
48%
6-10 YEARS
16%
>10 YEARS
11%
TIME SINCE
DIAGNOSIS
varies greatly
among patients;
~3 IN 4
were diagnosed in
the PAST 5
YEARS.
46%
53%
Good mix of locations by population
(54%) (46%)
(23%) (11%) (8%) (7%) (39%)
(21%)
(38%)
(21%)
(20%)
(26%) (21%)
(#) represents W3 (Q2 2021) data
1% said other
RURAL: 29% (27%)
TOWN/CITY: 49% (52%)
URBAN/METRO: 23% (21%)
9
9. RESPONDENT PROFILE – CAREGIVERS
Good mix of all ages: 50 YEARS (47) on average
Fairly regionally representative across
Canada
QUE 22%
ON 26%
AB 10%
BC 16%
SK 6% ATL 10%
MB 8%
<2 YEARS
44%
2-5 YEARS
32%
6-10 YEARS
14%
>10 YEARS
10%
TIME SINCE
DIAGNOSIS
varies but skews
towards more
recently diagnosed;
NEARLY HALF
were diagnosed
within the last 2
years
43%
57%
RURAL: 23% (21%)
TOWN/CITY: 52% (59%)
URBAN/METRO: 26% (19%)
Good mix of locations by population
RELATIONSHIP TO THE CANCER PATIENT
Spouse / partner
– 26%
Daughter (in-law)
– 16%
Mother (in-law) –
12%
Father (in-law) –
10%
Even split by gender
1 in 10 (11%) say they are unsure of their stage of cancer.
(64%) (36%)
Most common cancer types of
person being cared for
PROSTATE
CANCER: 17%
COLON / RECTAL
CANCER: 11%
BREAST
CANCER: 29%
LUNG
CANCER: 17%
(49%)
(36%)
(10%)
(5%)
(21%) (25%) (11%) (17%) (15%)
(25%) (12%) (6%) (11%)
(#) represents W3 (Q2 2021) data
10
10. Overall, ABOUT TWO-THIRDS were VERY SATISFIED with the QUALITY OF CANCER CARE received in
the past 6 months. Unaided, MORE respondents, especially patients, say this wave that they DON’T
HAVE CONCERNS ABOUT RECEIVING CARE even as COVID related restrictions are being lifted.
PATIENTS CAREGIVERS
SATISFACTION WITH QUALITY OF CANCER CARE RECEIVED IN THE PAST 6 MONTHS
10%
5%
15%
70%
Very satisfied
Somewhat satisfied
Somewhat unsatisfied /
not at all satisfied
Don’t know
6%
17%
34%
44% Very satisfied
Somewhat satisfied
Somewhat unsatisfied /
not at all satisfied
Don’t know
MAIN REASONS FOR BEING SOMEWHAT SATISFIED / SOMEWHAT UNSATISFIED / NOT AT ALL SATISFIED:
Unprofessional HCPs (losing files, forgetting appointments, not faxing prescriptions, etc.)
Status of appointments / treatment unknown
Not getting timely treatment / care / delays in services
Doctor not available / appointments cancelled
PATIENTS CAREGIVERS
MAIN CONCERN ABOUT RECEIVING CARE NOW THAT COVID-19 RESTRICTIONS ARE BEING LIFTED (UNAIDED)
18%
8%
5%
3%
46%
Access to health care (treatment, HCPs, tests, etc.)
Fear of getting COVID-19
Safety / Security / COVID-19 protocols
Fear of getting sick / concerned for health
None / no concerns
12%
19%
10%
9%
21%
Overall, 65% (vs. 56% in W3) are very
satisfied with the quality of care
received during COVID-19
Patients report higher satisfaction
with the quality of care received
this wave
Lack of organization in healthcare
system was highlighted as the
main reason for being unsatisfied
with quality of cancer care
received in the past 6 months
Unaided, significantly more
patients and caregivers say
they don’t have any concerns
about receiving care as
restrictions are being lifted.
Although less than last wave, a
few continue to be concerned
about access to healthcare and
contracting COVID-19
(60%)
(#) represents W3
(Q2 2021) data
(48%)
(19%)
(5%)
(-)
(27%)
(54%)
(24%)
(9%)
(-)
(6%)
11
11. HEALTHCARE PROVIDERS INTERACTED WITH IN THE PAST 6 MONTHS
AMONG THOSE WHO
INTERACTED WITH EACH
PHYSICIAN IN THE PAST
6 MONTHS
PATIENTS are MORE LIKELY to have INTERACTED with an HCP IN THE PAST 6 MONTHS versus during the
pandemic. SIGNIFICANT INCREASE reported in IN-PERSON CONSULTATIONS, however, VIRTUAL
CONSULTATIONS continue to be WIDELY USED.
PATIENTS CAREGIVERS
70%
60%
40%
32%
Specialists
Family doctor/ GP
Pharmacists
Allied healthcare professionals
73%
81%
60%
55%
(61%)
(54%)
(79%)
(80%)
(67%)
(64%)
Patients are significantly more likely to have
interacted with HCPs in the past 6 months
vs. during the pandemic
Patients in ON, QC and MB are more likely
to have consulted a specialist in the past 6
months vs. other provinces
Recently diagnosed patients are more likely
to say they have interacted with specialists
(92%) and GPs (74%) in the past 6 months
(34%)
(27%)
Overall, physician interactions are
significantly more likely to have
been in-person in the past 6
months
Drop in virtual interactions in the
past 6 months; however, two-
thirds continue to interact with
GPs virtually and about half with
specialists
Among all virtual modes of
interactions, telephone consults
continue to be used the most
MODES OF INTERACTION IN
THE PAST 6 MONTHS
77%
62%
66%
55%
GPs Specialists
In-person
Virtual
(telephone, video consult,
e-mail, instant messaging,
text / SMS)
94%
91%
89%
90%
79%
67%
67%
50%
GPs Specialists
86%
92%
85%
85%
(79%)
(61%)
(79%)
(64%)
(59%)
(68%)
(63%)
(58%)
MAIN REASONS FOR BEING SOMEWHAT UNSATISFIED / NOT AT ALL SATISFIED WITH VIRTUAL CONSULTS:
Would rather have an in-person consult
Found it difficult communicating virtually
Bad service (lack of follow up, vague answers, misdiagnosis, etc.)
It was hard to access physician
Some concerns were not addressed
SATISFACTION
(VERY/SOMEWHAT
SATISFIED)
SATISFACTION
(VERY/SOMEWHAT
SATISFIED)
(#) represents W3 (Q2 2021) data
12
12. With relaxation in COVID-19 related restrictions, LEVEL OF ANXIETY about RECEIVING ADEQUATE CANCER
CARE is likely to RISE AGAIN.
LEVEL OF ANXIETY* ABOUT RECEIVING ADEQUATE CANCER CARE
*% VERY + SOMEWHAT CONCERNED
50%
43%
33%
39%
73%
70%
57% 59%
Patients Caregivers
AS COVID-19 WAS
BEING DECLARED
A PANDEMIC
(no vaccines available in
March 2020)
DURING SECOND /
THIRD WAVE
[when vaccines started to be
available / were available
(between January and April 2021)]
DURING FOURTH WAVE
[as boosters became available
(between December 2021 and
February 2022)]
NOW AS RESTRICTIONS
ARE BEING RELAXED
Female patients (42%) report being more anxious than male patients (35%) about receiving adequate cancer care now that restrictions are being lifted.
Recently diagnosed patients (49%) are more anxious than those diagnosed 2+ years ago.
Patients (42%) and Caregivers in urban areas (69%) are more are more anxious about them / the person they care for receiving adequate cancer care.
NOTE: RECENTLY DIAGNOSED = DIAGNOSED <2 YEARS AGO
13
13. *% VERY + SOMEWHAT
CONCERNED
When prompted, patients as well as caregivers report SIGNIFICANT INCREASE IN CONCERNS about
RECEIVING ADEQUATE CARE (compared to last wave) now that COVID-19 restrictions are being lifted.
Ability to be cared for in ER
Ability to receive hospital care other than ER
Being able to receive cancer treatment in a timely fashion
Being able to get tests related to cancer
Being able to get help for side effects or new symptoms
Coverage and funding of new treatments
Being able to receive post-treatment rehabilitative care
Being able to see the doctor managing my cancer in-person
Availability of new cancer treatments
Shortages of medication to treat and/or manage my cancer
TOTAL PATIENTS CAREGIVERS
55%
53%
51%
47%
46%
45%
45%
42%
42%
41%
52%
49%
47%
42%
42%
41%
39%
38%
38%
36%
67%
68%
66%
67%
63%
60%
65%
58%
57%
58%
MAIN CONCERNS* ABOUT FOLLOWING NOW THAT COVID-19 RESTRICTIONS ARE BEING LIFTED
Unaided, contracting COVID-19 continues to be the main concern for all, more so among caregivers, and more than previous wave
About half feel comfortable visiting a hospital or ER for cancer care. Those who do not feel comfortable suggest variety of
measures that would make them feel comfortable, including:
• Strictly following COVID-19 safety guidelines, including maintaining mask mandates
• Seen in a timely manner / getting an appointment
• Everyone be fully vaccinated / Mandatory vaccination
• Cleanliness / sanitary measures in place
32%
31%
34%
28%
30%
32%
27%
26%
30%
23%
W3
57%
56%
60%
54%
60%
57%
57%
57%
54%
50%
W3
38%
37%
42%
34%
36%
38%
34%
37%
36%
31%
W3
14
14. COVID-19 CONTINUES to AFFECT MOST ASPECTS of everyone’s life, causing FEARS that their CANCER
WILL PROGRESS and IMPACTING OVERALL STATE of HEALTH and WELLBEING.
TOTAL PATIENTS CAREGIVERS
AFFECT* OF COVID-19 ON THE FOLLOWING ASPECTS OF LIFE
NOTE: RECENTLY DIAGNOSED = DIAGNOSED <2 YEARS AGO
* % SIGNIFICANT + SOME AFFECT
Your overall state of health and wellbeing
Fears that your cancer will progress
Mental health
Exercise
Time to care for others in your family
Financial wellbeing
Diet/ nutrition
Ability to work (inside or outside the home)
52%
49%
47%
46%
40%
38%
34%
30%
48%
42%
42%
42%
34%
33%
29%
25%
71%
75%
70%
62%
67%
60%
54%
49%
(44%)
(39%)
(27%)
(22%)
STAGE 2 – 57%
RECENTLY DIAGNOSED – 56%
RECENTLY DIAGNOSED – 56%
(#) represents W3 (Q2 2021) data
15
15. HALF of those surveyed mentioned that they are NOT COMFORTABLE with their PROVINCIAL GOVERNMENT
LIFTING RESTRICTIONS. Although many say that this would have no impact on daily life as they would continue to
follow safety measures, 1 in 5 say it would have a NEGATIVE IMPACT.
PERCEPTIONS ABOUT EASING COVID-19 RESTRICTIONS
PATIENTS CAREGIVERS
1%
49%
30%
20%
Very comfortable
Somewhat comfortable
not very / not at all
comfortable
Don’t know
7%
51%
24%
18%
Very comfortable
Somewhat comfortable
Not very / not at all
comfortable
Don’t know
LEVEL OF COMFORT WITH PROVINCIAL GOVT
LIFTING COVID-19 RESTRICTIONS
MAIN REASONS FOR VERY/
SOMEWHAT COMFORTABLE
(UNAIDED):
Need to learn to live with it /
Tired of it all / It's been two
years
We are capable of managing
the risk ourselves
The virus is not as serious/
dangerous as it once was
Herd immunity
MAIN REASONS FOR NOT VERY/NOT
AT ALL COMFORTABLE (UNAIDED):
COVID-19 cases are going up
It's too soon / too early
Masks/Restrictions should be
maintained
COVID-19 is still here / Not over
yet
Afraid to catch COVID-19 /
immunocompromised / at risk
New variants / Another wave
56%
19%
25%
45%
20%
13%
NO
IMPACT
NEGATIVE
IMPACT
POSITIVE
IMPACT
• Continue to follow
COVID-19 / safety
protocols
• Avoid going out /
crowded places
• Increased stress /
anxiety / fear
• Stay home more /
more isolated
• Afraid to catch COVID
• Able to get out more
• Able to see friends/
family
• Freedom
• We need to learn to
live with it
34%
20%
13%
14%
11%
18%
9%
7%
4%
4%
Continue to follow
COVID-19 protocols
(NET)
Mask mandates /
wearing masks
COVID-19 protocols
other than masks
More/Better
vaccinations/boosters
More info / Bring back
daily updates
PATIENTS CAREGIVERS
IMPACT OF RELAXATION OF
RESTRICTIONS ON DAILY LIFE
(UNAIDED)
MAIN SUGGESTIONS FOR GOVT TO
MAKE PEOPLE FEEL MORE
COMFORTABLE NOW THAT
RESTRICTIONS ARE BEING LIFTED
(UNAIDED)
16
16. Even as COVID-19 related restrictions being to lift, patients as well as caregivers indicate HIGH LIKELIHOOD to
CONTINUE FOLLOWING THE SAFETY PROTOCOLS, including WEARING A MASK IN PUBLIC.
PATIENTS
COVID-19 RISK ASSESSMENT
ABOUT THREE-QUARTERS ANTICIPATE THAT THEY /
PERSON THEY CARE FOR WOULD CONTINUE TO WEAR A
MASK FOR THE FORSEEABLE FUTURE. REST ANTICIPATE
WEARING IT FOR, ON AVERAGE, 6 MONTHS OR MORE.
MAIN REASONS TO CONTINUE TO WEAR A MASK
(UNAIDED):
To stay safe / reduce risk / remain cautious
COVID-19 is still here / not over yet
Afraid of catching COVID-19 /
immunocompromised at risk
Continue wearing a mask as long as necessary
/ certain settings
New variants / Another wave
COVID-19 cases are going up
CAREGIVERS
50%
50%
43%
43%
44%
45%
34%
42%
Provincial Chief
Medical Officer of
Health
Provincial Ministry of
Health
Federal Chief Medical
Officer of Health
Local Public Health
Officials
26% PATIENTS report being told by
a physician that they are
immunocompromised. This number
rises to 41% among CAREGIVERS for
the person they care for
*% VERY + SOMEWHAT LIKELY
93%
83%
82%
73%
61%
58%
32%
32%
92%
84%
83%
78%
62%
69%
39%
53%
Wash / sanitize my hands
frequently
Keep socially distanced
WEAR A MASK IN PUBLIC
Avoid seeing people in large
groups
Continue to use virtual
appointments
Use online sources for
shopping
Avoid in-person appointments
Avoid going to stores
PUBLIC HEALTH GUIDANCE
FOLLOWED FOR OWN RISK
ASSESSMENT
LIKELIHOOD* TO CONTINUE TO DO THE
FOLLOWING NOW THAT COVID-19
RESTRICTIONS ARE BEING LIFTED
17
17. COVID-19 VACCINATION
HIGH VACCINATION RATES among those surveyed, with MOST having RECEIVED two doses and a
booster dose. HIGH LIKELHOOD to get ANOTHER BOOSTER dose if made available and recommended by
the government.
PATIENTS CAREGIVERS
96% 89%
PERSON CAREGIVER
IS TAKING CARE OF
87%
% RECEIVED A
COVID-19 VACCINE
3% PATIENTS and about 7% CAREGIVERS / PERSON THEY CARE FOR do not intend to take COVID-19 vaccine, mainly because they are
concerned about side effects and they feel the vaccines are not tested enough, they don’t trust the vaccines and vaccines are ineffective
0%
9%
91%
2%
14%
84%
2%
20%
78%
One dose
Two doses
Two doses and a booster dose
80% 73%
73%
11% patients say they have
been tested to see if COVID-
19 vaccine works for them
22% caregivers say person they
care for have been tested to see if
COVID-19 vaccine works for them
% HAD COVID-19
PATIENTS
16%
Among patients who had COVID-19:
• Vast majority had mild /
moderate COVID
• 16% say they have LONG COVID
(n=171)
PERSON CAREGIVER
IS TAKING CARE OF
18%
Among caregivers who say person
they care for have had COVID-19:
• 4 in 5 had mild / moderate COVID
• 38% say they have LONG COVID
(n=45)
% LIKELY TO GET
ANOTHER
BOOSTER SHOT
18
18. CONCLUSIONS
OVERALL, NEARLY TWO-THIRDS (65%) say they were HIGHLY SATISFIED WITH THE QUALITY OF CANCER CARE received in the past 6
months. PATIENTS report being MUCH MORE SATISFIED this wave compared to last wave (Q2, 2021).
• Unaided, SIGNIFICANT INCREASE in proportion who say they DON’T HAVE ANY CONCERNS about RECEIVING CARE now that
restrictions are being lifted. This wave, CLOSE TO HALF of the PATIENTS (46% vs. 27% in W3) and 1 IN 5 CAREGIVERS (21% vs.
6% in W3) report NO CONCERNS. Among those who have concerns, ACCESS TO HEALTHCARE and CONTRACTING COVID-19
CONTINUE to be main concerns (although less than last wave).
MAJORITY of patients and caregivers report having INTERACTED with a PHYSICIAN in the PAST 6 MONTHS. Patients are significantly
more likely to have interacted with HCPs in the past 6 months vs. during the pandemic.
• While NOTICEABLE INCREASE observed in IN-PERSON CONSULTATIONS, VIRTUAL CONSULTATIONS, especially via telephone,
continue to be WIDELY USED.
• Overall, high satisfaction reported with all modes of interactions.
Both patients and caregivers mention that their ANXIETY LEVELS about RECEIVING ADEQUATE CANCER CARE DROPPED SIGNIFICANTLY
THROUGHOUT THE PANDEMIC from its peak when COVID-19 was declared a pandemic up to early this year when booster doses
became available; however, NOW AS RESTRICTIONS BEGIN TO LIFT, ANXIETY LEVELS ARE STARTING TO SHOW AN UPWARD TREND.
• When prompted, respondents indicate that they are QUITE CONCERNED about their ability to be CARED FOR IN AN ER or a
HOSPITAL, SEE A DOCTOR IN-PERSON and being able to GET TESTS AND TREATMENT IN A TIMELY MANNER as restrictions
begin to be lifted.
1
2
3
19
19. CONCLUSIONS
HALF of the patients and caregivers surveyed say that they are NOT COMFORTABLE with their PROVINCIAL GOVERNMENT LIFTING
RESTRICTIONS, mainly because they feel COVID IS NOT OVER YET, it CONTINUES TO BE A THREAT and that IT IS TOO SOON.
• 1 in 5 believe RELAXATION OF RESTRICTIONS will have a NEGATIVE IMPACT on their daily life as they would avoid going out /
avoid crowded places, stay home more / more isolated and it’ll increase stress/anxiety/fear.
• To make them FEEL MORE COMFORTABLE, respondents suggest that government should CONTINUE WITH COVID-19
PROTOCOLS, including MASK MANDATES.
Even as COVID-19 related restrictions being to lift, patients as well as caregivers indicate HIGH LIKELIHOOD to CONTINUE FOLLOWING
COVID-19 SAFETY MEASURES.
• 4 in 5 say they would CONTINUE TO WEAR A MASK. MAJORITY of those anticipate wearing it FOR THE FORESEEABLE FUTURE
while REST for, on average, 6 MONTHS OR MORE.
ALMOST UNIVERSAL COVERAGE of COVID-19 VACCINE among those surveyed, with MAJORITY vaccinated with TWO DOSES AND A
BOOSTER DOSE.
• ~1 IN 6 RESPONDENTS (16% patients and 18% caregivers say the person they care for) have HAD COVID-19, with the vast
majority reporting it was mild/moderate. Although on a low sample size, among patients who have had COVID-19, 1 in 6
(16%) are suffering from long COVID. This number rises to 2 in 5 among caregivers.
4
5
6
20
20. CANADIAN CANCER SURVIVOR NETWORK
CONTACT INFO
1750 Courtwood Crescent, Suite 210
Ottawa, ON K2C 2B5
Telephone / Téléphone : 613-898-1871
E-mail: jmanthorne@survivornet.ca or info@survivornet.ca
Website: www.survivornet.ca
Twitter: @survivornetca
Facebook: www.facebook.com/CanadianSurvivorNet
Instagram: @survivornet_ca
Pinterest: http://pinterest.com/survivornetwork/
21